|
|
||||||||
From the Preston Robert Tisch Brain Tumor Center (S.S., A.D., D.A.R., J.N.R., J.J.V.), Departments of Medicine (S.S., A.D., J.N.R., J.J.V.), Surgery (D.A.R., J.N.R.), and Neurobiology (J.N.R.), Duke University Medical Center, Durham, NC.
Address correspondence and reprint requests to Dr. Sith Sathornsumetee, The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, DUMC 3624, Durham, NC 27710; e-mail: satho001{at}mc.duke.edu
A 45-year-old woman developed a gradual onset of sensorineural hearing loss in the left ear in 1984. Head CT scan with contrast demonstrated bilateral cerebellopontine angle (CPA) enhancing masses. She underwent a resection of the left CPA tumor with pathology confirming schwannoma. Despite several resections, she had progressive hearing loss and she became deaf in 2003. Her brain MRI (figure) demonstrated bilateral vestibular schwannomas, which are sufficient for a definite diagnosis of neurofibromatosis type 2 (NF-2), according to the National Institutes of Health, Manchester, or National Neurofibromatosis Foundation diagnostic criteria.1 In addition, this patient also has multiple meningiomas, which are associated with NF-2.2 The patient has been treated with imatinib mesylate (Gleevec) plus hydroxyurea in a clinical trial for her progressive meningiomas. At her last follow-up visit, she was neurologically and radiographically stable after 12 months of treatment.
|
Footnotes
Disclosure: The authors report no conflicts of interest.
Received August 11, 2006. Accepted in final form November 27, 2006.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |